Finance
UK watchdog says it may accept remedies in $35 billion Synopsys-Ansys deal
Published by Global Banking & Finance Review®
Posted on January 8, 2025
1 min readLast updated: January 27, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on January 8, 2025
1 min readLast updated: January 27, 2026
The UK's CMA may accept proposed remedies for the $35 billion Synopsys-Ansys deal, including divestments to address competition concerns.
(Reuters) -The UK's competition regulator said on Wednesday it might accept remedies offered by chip design software maker Synopsys and Ansys to address the concerns raised over their $35 billion deal.
Synopsys announced its cash-and-stock deal for Ansys, whose software is used to make products ranging from airplanes to tennis rackets, in January last year.
The Competition and Markets Authority said the undertakings offered on Dec. 31 included the divestment of Ansys' power consumption analysis product for digital chips and Synopsys' sale of its global optics and photonics software business.
The CMA said it has until March 5 to decide whether to accept the undertakings, with the possibility to extend the deadline to May 6.
A Synopsys spokesperson said the companies are pleased with the regulator's decision, adding that the duo will maintain its "constructive and collaborative engagement" with the CMA.
(Reporting by Aby Jose Koilparambil and Prerna Bedi in Bengaluru; Editing by Shilpi Majumdar)
The main topic is the UK's CMA considering remedies for the $35 billion Synopsys-Ansys deal to address competition concerns.
Proposed remedies include the divestment of Ansys' power consumption analysis product and Synopsys' optics and photonics software.
The CMA has until March 5 to decide on the remedies, with a possible extension to May 6.
Explore more articles in the Finance category
